202 related articles for article (PubMed ID: 32250255)
1. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care.
Mrowietz U; Sorbe C; Reich K; Von Kiedrowski R; Weckbecker J; Radtke MA; Rustenbach SJ; Augustin M
Eur J Dermatol; 2020 Feb; 30(1):41-48. PubMed ID: 32250255
[TBL] [Abstract][Full Text] [Related]
2. Oral fumaric acid esters for psoriasis.
Atwan A; Ingram JR; Abbott R; Kelson MJ; Pickles T; Bauer A; Piguet V
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010497. PubMed ID: 26258748
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions.
Inzinger M; Weger W; Heschl B; Salmhofer W; Quehenberger F; Wolf P
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):861-6. PubMed ID: 22672248
[TBL] [Abstract][Full Text] [Related]
4. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
Dickel H; Bruckner T; Altmeyer P
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
[TBL] [Abstract][Full Text] [Related]
5. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
Tzaneva S; Geroldinger A; Trattner H; Tanew A
Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862
[TBL] [Abstract][Full Text] [Related]
6. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
Balasubramaniam P; Stevenson O; Berth-Jones J
Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
[TBL] [Abstract][Full Text] [Related]
7. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
Zidane M; Dressler C; Gaskins M; Nast A
JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE).
Reich K; Thaci D; Mrowietz U; Kamps A; Neureither M; Luger T
J Dtsch Dermatol Ges; 2009 Jul; 7(7):603-11. PubMed ID: 19459898
[TBL] [Abstract][Full Text] [Related]
9. Fumaric acid esters for psoriasis: a systematic review.
Smith D
Ir J Med Sci; 2017 Feb; 186(1):161-177. PubMed ID: 27271164
[TBL] [Abstract][Full Text] [Related]
10. German psoriasis registry PsoBest: objectives, methodology and baseline data.
Augustin M; Spehr C; Radtke MA; Boehncke WH; Luger T; Mrowietz U; Reusch M; Strömer K; Wozel G; von Kiedrowski R; Rustenbach SJ; Purwins S; Reich K
J Dtsch Dermatol Ges; 2014 Jan; 12(1):48-57. PubMed ID: 24393314
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions - a retrospective evaluation (FACTS).
Thaçi D; Weisenseel P; Philipp S; Rosenbach T; Rotterdam S; Augustin M; Neureither M; Reich K
J Dtsch Dermatol Ges; 2013 May; 11(5):429-35. PubMed ID: 23433431
[TBL] [Abstract][Full Text] [Related]
12. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
[TBL] [Abstract][Full Text] [Related]
13. Nail psoriasis improvement in a patient treated with fumaric acid esters.
Vlachou C; Berth-Jones J
J Dermatolog Treat; 2007; 18(3):175-7. PubMed ID: 17538807
[TBL] [Abstract][Full Text] [Related]
14. Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.
Mason KJ; Williams S; Yiu ZZN; McElhone K; Ashcroft DM; Kleyn CE; Jabbar-Lopez ZK; Owen CM; Reynolds NJ; Smith CH; Wilson N; Warren RB; Griffiths CEM
Br J Dermatol; 2019 Aug; 181(2):256-264. PubMed ID: 30628069
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fumaric acid esters in combination with phototherapy in patients with moderate-to-severe plaque psoriasis (FAST).
Weisenseel P; Reich K; Griemberg W; Merten K; Gröschel C; Gomez NN; Taipale K; Bräu B; Zschocke I
J Dtsch Dermatol Ges; 2017 Feb; 15(2):180-186. PubMed ID: 28214304
[TBL] [Abstract][Full Text] [Related]
16. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study).
Reich K; Hartl C; Gambichler T; Zschocke I
J Dtsch Dermatol Ges; 2016 Jan; 14(1):50-8. PubMed ID: 26713639
[TBL] [Abstract][Full Text] [Related]
17. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
van de Kerkhof PCM; Loewe R; Mrowietz U; Falques M; Pau-Charles I; Szepietowski JC
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):119-126. PubMed ID: 31465585
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
Landeck L; Asadullah K; Amasuno A; Pau-Charles I; Mrowietz U
Arch Dermatol Res; 2018 Aug; 310(6):475-483. PubMed ID: 29574575
[TBL] [Abstract][Full Text] [Related]
19. Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis.
Dickel H; Bruckner T; Höxtermann S; Dickel B; Trinder E; Altmeyer P
J Eur Acad Dermatol Venereol; 2019 May; 33(5):893-905. PubMed ID: 30680823
[TBL] [Abstract][Full Text] [Related]
20. Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial.
Holzer G; Hoke M; Sabeti-Sandor S; Perkmann T; Rauscher A; Strassegger B; Radakovic S; Tanew A
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):441-449. PubMed ID: 32426884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
